GTC Biotherapeutics (fka GTCB)

[jessellivermore]

Clearly this is the important point. GTCB in addition to having the patents also has the choice of operating in areas where they have an unfair advantage. This is in the production of proteins which are difficult to produce in bulk using cell systems, eg plasma proteins. GTCB's entente cordial with LFB shows this is their intent.

Glycolisation paterns of TPP (transgenically produced proteins) are probably going to vary from their plasma derived cousins unpredictably (almost always the case at this level of complexity) The clinical differences will be studied and judged. This is pretty much the way of medicine.